Cargando…

International comparison of the factors influencing reimbursement of targeted anti-cancer drugs

BACKGROUND: Reimbursement policies for anti-cancer drugs vary among countries even though they rely on the same clinical evidence. We compared the pattern of publicly funded drug programs and analyzed major factors influencing the differences. METHODS: We investigated reimbursement policies for 19 i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Carol Sunghye, Lee, Yun-Gyoo, Koh, Youngil, Heo, Dae Seog
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258032/ https://www.ncbi.nlm.nih.gov/pubmed/25432511 http://dx.doi.org/10.1186/s12913-014-0595-0

Ejemplares similares

Anthelmintics as Potential Anti-Cancer Drugs?
por: Heo, Dae Seog
Publicado: (2020)

Abstract: 11.50 An International Comparison Of Reimbursement For Dieap Flap Breast Reconstruction
por: Szpalski, Caroline, et al.
Publicado: (2017)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
por: Macabeo, Bérengère, et al.
Publicado: (2023)

Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List
por: Liu, Wenbin, et al.
Publicado: (2019)

Profit-Influencing Factors in Orthopedic Surgery: An Analysis of Costs and Reimbursements
por: Rohrer, Felix, et al.
Publicado: (2022)

Pricing and reimbursement of novel oncology drugs in Sweden
por: Haglund, Mattias, et al.
Publicado: (2014)

Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
por: Lee, Jong Hyuk
Publicado: (2021)

Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches
por: Nicod, Elena, et al.
Publicado: (2020)

An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries
por: Ward, Leanne Marie, et al.
Publicado: (2022)

Reimbursement and economic factors influencing dialysis modality choice around the world
por: Just, Paul M., et al.
Publicado: (2008)

Reimbursement for reconstruction by tissue transfer–a European comparison
por: Lotter, Oliver, et al.
Publicado: (2014)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

Reimbursement of orphan drugs in Belgium: what (else) matters?
por: Picavet, Eline, et al.
Publicado: (2014)

Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
por: van den Brink, Rinke
Publicado: (2014)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France
por: Squara, Pierre-Alexandre, et al.
Publicado: (2022)

Assessing the effects of National Health Insurance reimbursement policy revisions for anti-osteoporotic drugs in Korean women aged 50 or older
por: Koo, Ja Seo, et al.
Publicado: (2020)

The evolution of Taiwan’s National Health Insurance drug reimbursement scheme
por: Hsu, Jason C, et al.
Publicado: (2015)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

A systematic review of moral reasons on orphan drug reimbursement
por: Zimmermann, Bettina M., et al.
Publicado: (2021)

Use of health technology assessment in drug reimbursement decisions in China
por: Chen, Wen, et al.
Publicado: (2023)

Use of health technology assessment in drug reimbursement decisions in China
Publicado: (2023)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
por: Zhu, Xingyue, et al.
Publicado: (2023)

Reimbursement of Bus Fares
Publicado: (1954)

The History of Reimbursements in Neurology
por: Lakhan, Shaheen E., et al.
Publicado: (2013)

Introduction: Pharmacy Reimbursement
por: Greenwood, Bonnie C.
Publicado: (2020)

Effects of the Revised Reimbursement Guideline for Anti-Osteoporosis Medication in South Korea
por: Ko, Young-Seung, et al.
Publicado: (2022)

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans
por: Salek, Sam, et al.
Publicado: (2019)

How is Clinical Trial Reimbursement Money Spent? South African Trial Participants’ Reported Reimbursement Spending Patterns and Perceptions of Appropriate Reimbursement Amounts
por: Milford, Cecilia, et al.
Publicado: (2021)

Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries
por: Atikeler, Enver Kagan, et al.
Publicado: (2016)

CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome
por: Park, Songyi, et al.
Publicado: (2023)

Assessment of Methodological Quality of Economic Evaluations in Belgian Drug Reimbursement Applications
por: Simoens, Steven
Publicado: (2013)

Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
por: Docteur, Elizabeth, et al.
Publicado: (2015)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Outdated criteria for drug plan reimbursement obstruct evidence-based care
por: Bayoumi, Ahmed, et al.
Publicado: (2021)

A comment on participant reimbursement within Australian drug and alcohol research
por: Winter, Daniel T., et al.
Publicado: (2022)

Income Tax Exemption and Reimbursement
Publicado: (1955)

The Reimbursement Maxima of the Education Grant
Publicado: (1982)

The Reimbursement Maxima of the Education Grant
Publicado: (1980)

Cannot write session to /tmp/vufind_sessions/sess_bsgu8nvl54ektifi99m39nm5s3